Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Unknown 40Recruiting 12Not yet recruiting 11Completed 4Active not recruiting 4Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Breast 4

Conditions

Breast Neoplasms 4HER2-positive Breast Cancer 2Non-squamous NSCLC 1Non Small Cell Lung 1HER2 Positive Breast Cancer 1

Interventions

Trastuzumab 350Paclitaxel 334Cyclophosphamide 315Docetaxel 291Capecitabine 181Doxorubicin 180Letrozole 166Tamoxifen 145Bevacizumab 124Fulvestrant 118Carboplatin 118exemestane 111Lapatinib 111Anastrozole 111Radiotherapy 105Epirubicin 104Gemcitabine 97palbociclib 84Exercise 78Vinorelbine 77Fluorouracil 77Surveys and Questionnaires 71pertuzumab 67Filgrastim 64Albumin-Bound Paclitaxel 64eribulin 55Magnetic Resonance Spectroscopy 55Everolimus 52Blood Specimen Collection 51Zoledronic Acid 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × Breast Neoplasms × pyrotinib × Clear all
NCT05572645 2024-02-26

Pyrotinib Plus Trastuzumab Versus Pertuzumab Plus Trastuzumab

Fudan University

Completed
333 enrolled
Breast

Breast Neoplasms

NCT04367090 2023-09-18

Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
97 enrolled
Breast

Breast Neoplasms

NCT05252546 2022-12-23

Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
36 enrolled
Breast

Breast Neoplasms

NCT01937689 2018-07-09

Study of Pyrotinib in Patients With Human Epidermalgrowth Factor Receptor 2 (HER2) Positive Advanced Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
40 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡